• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    Lipocine Inc. (LPCN)

    9.07 Up 0.03(0.33%) May 27, 4:00PM EDT
    ProfileGet Profile for:
    Lipocine Inc.
    675 Arapeen Drive
    Suite 202
    Salt Lake City, UT 84108
    United States - Map
    Phone: 801-994-7383
    Fax: 801-994-7388
    Website: http://www.lipocine.com

    Index Membership:N/A
    Industry:Drugs - Generic
    Full Time Employees:25

    Business Summary 

    Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate, LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing that has completed Phase 3 testing. The company’s pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase 2 testing; and LPCN 1107, which is in Phase 1 testing for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Lipocine Inc.

    Key Executives 
    Dr. Mahesh V. Patel Ph.d., 59
    Co-Founder, Chairman, Chief Exec. Officer and Pres
    Mr. Morgan R. Brown CPA, MBA, 48
    Chief Financial Officer, Exec. VP and Corp. Sec.
    Dr. Jyrki Mattila M.D., Ph.D., MBA, 61
    Chief Bus. Officer and Exec. VP
    Dr. William I. Higuchi Ph.D., 85
    Chief Scientific Consultant
    Dr. Anthony DelConte M. D., 58
    Chief Medical Director
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders